Scotiabank initiated coverage of Blueprint Medicines (BPMC) with an Outperform rating and $150 price target Stock performance has been “choppy,” but greater appreciation of the company’s $4B systemic mastocytosis franchise, elenestinib, which is “not getting the attention it deserves,” and proof of concept data from BLU-808 studies should drive shares higher, the analyst tells investors. BLU-808 could be Blueprint’s “largest opportunity yet,” the analyst added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BPMC:
- Blueprint Medicines: Hold Rating Amid Concerns Over Ayvakit’s Liver Function Test Elevations
- Cautious Optimism: Hold Rating Given to Blueprint Medicines Amid Financial Performance Concerns and Slower Ayvakit Growth Projections
- Blueprint Medicines price target raised to $135 from $127 at Baird
- Strong Buy Rating for Blueprint Medicines: Ayvakit’s Growth Potential and Market Opportunities
- Blueprint Medicines Reports Strong Growth and Promising Outlook